April 13, 2021
Civil Society Letter to New WTO Director General: Access to COVID-19 Medical Products
Letter / Comment
TAG joined over 200 other civil society signatories in calling for Dr. Ngozi Okonjo-Iweala, incoming Director General of the World Trade Organization, to move away from interventions to scale up global vaccine supplies for COVID-19 that emphasize biopharmaceutical control of vaccine production and eschew public transparency.
April 6, 2021
Community Update on Current and Future COVID-19 Vaccine Trials
On Tuesday, April 6th Treatment Action Group (TAG) hosted a webinar for community advocates with a status update on current and future COVID-19 vaccine trials and answers to questions related to safety and efficacy data.
April 6, 2021
TAG EU and UK TB Research and Development Advocacy Consultant
TAG is seeking a consultant to advance strategic policy-advocacy and resource mobilization efforts for TB R&D in the context of EU and UK global development cooperation. The consultant will be responsible for engaging policymakers, investigating legislative opportunities, and executing advocacy strategies in collaboration with TAG to increase TB R&D resources…
April 4, 2021
TAG Comments on NIST’s Proposed Rulemaking Changes
Letter / Comment
TAG submitted comments in response to the National Institute of Standards and Technology’s (NIST) proposed change to rulemaking, strongly opposing amendments to remove crucial public health safeguards from the Bayh-Dole Act. March-in rights and other provisions to hold manufacturers accountable when federally funded inventions are exorbitantly priced and are critically…
April 1, 2021
Civil Society Letter to Donors, Countries, and Health Actors to Improve Access to GeneXpert and Other Diagnostics
Letter / Comment
TAG led an open letter appealing to donors, countries, and health actors to improve access to GeneXpert and other diagnostics for COVID-19, TB, HIV, HBV, HCV, and other diseases by applying collective leverage in negotiations with Cepheid for lower prices and sufficient volumes; establishing cost-of-goods-sold (COGS)-plus and volume-based pricing for…